Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your genes may decide your painkiller: a trial puts personalized dosing to the test

NCT ID NCT05657704

Disease control Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether a simple genetic test can help doctors choose the right painkiller for people recovering from wisdom tooth surgery. Participants are randomly assigned to either standard care or a genetic-guided approach, where their DNA determines if they get tramadol or an alternative painkiller. The goal is to see if personalized dosing improves pain relief and reduces side effects compared to usual practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Genetic testing to guide pain medication choice (tramadol or dexketoprofen)
What this could lead to
If it works, this could make postoperative pain relief more personalized, improving pain control and reducing side effects for many patients.
What could go wrong
The trial is relatively small and early, and genetic testing may not always predict how well a drug works in every person. Some patients may still experience pain or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women over 18 years of age. * Patients scheduled for outpatient surgical extraction, under local anesthesia, of at least two impacted third molars, at least one of which will require bone removal. * Patients who agree to participate in the study and give written consent. Exclusion Criteria: * Patients under treatment with other drugs that can inhibit CYP2D6, or are contraindicated in combination with tramadol or dexketoprofen. * Patients on treatment with bisphosphonates. * Patients who are receiving analgesic treatment before the operation, 24 hours prior to the operation. This criterion will be evaluated at the intervention visit. * Patients suffering from other uncontrolled diseases. * Pregnant or breastfeeding women. * Patients with contraindications for treatment with tramadol or dexketoprofen.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pain, acute are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pain, acute Post-surgical pain Postoperative pain

Contacts and locations

Locations

  • Fundación para la Investigación Biomédica Hospital La Princesa

    Madrid, 28006, Spain

  • Hospital General Universitario de Burgos y Clínica Colina

    Burgos, 09006, Spain

  • Hospital Universitario Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, 28220, Spain

  • Hospital Universitario San Juan de Alicante

    Alicante, 03550, Spain

  • Hospital Universitaro La Paz

    Madrid, 28046, Spain

  • Hospital Univesitario Ramón y Cajal

    Madrid, 28034, Spain

  • Hostpital Universitario Fundación Jiménez Díaz

    Madrid, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.